# Limosilactobacillus Reuteri as an Adjuvant in the Treatment of Peri-implant Mucositis

> **NCT05758103** · NA · COMPLETED · sponsor: **Malo Clinic** · enrollment: 32 (actual)

## Conditions studied

- Peri-implant Mucositis

## Interventions

- **DIETARY_SUPPLEMENT:** Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)

## Key facts

- **NCT ID:** NCT05758103
- **Lead sponsor:** Malo Clinic
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-05
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-09-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05758103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05758103, "Limosilactobacillus Reuteri as an Adjuvant in the Treatment of Peri-implant Mucositis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05758103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*